Global Anti-VEGF Drugs for Angiogenesis-related Disease Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Anti-VEGF Drugs for Angiogenesis-related Disease market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
The Global Info Research report includes an overview of the development of the Anti-VEGF Drugs for Angiogenesis-related Disease industry chain, the market status of Tumor (Ranibizumab, Brolucizumab), Eye Diseases (Ranibizumab, Brolucizumab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Anti-VEGF Drugs for Angiogenesis-related Disease.
Regionally, the report analyzes the Anti-VEGF Drugs for Angiogenesis-related Disease markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Anti-VEGF Drugs for Angiogenesis-related Disease market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Anti-VEGF Drugs for Angiogenesis-related Disease market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Anti-VEGF Drugs for Angiogenesis-related Disease industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Ranibizumab, Brolucizumab).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Anti-VEGF Drugs for Angiogenesis-related Disease market.
Regional Analysis: The report involves examining the Anti-VEGF Drugs for Angiogenesis-related Disease market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Anti-VEGF Drugs for Angiogenesis-related Disease market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Anti-VEGF Drugs for Angiogenesis-related Disease:
Company Analysis: Report covers individual Anti-VEGF Drugs for Angiogenesis-related Disease manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Anti-VEGF Drugs for Angiogenesis-related Disease This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Tumor, Eye Diseases).
Technology Analysis: Report covers specific technologies relevant to Anti-VEGF Drugs for Angiogenesis-related Disease. It assesses the current state, advancements, and potential future developments in Anti-VEGF Drugs for Angiogenesis-related Disease areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Anti-VEGF Drugs for Angiogenesis-related Disease market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Anti-VEGF Drugs for Angiogenesis-related Disease market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Anti-VEGF Drugs for Angiogenesis-related Disease product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease, with price, sales, revenue and global market share of Anti-VEGF Drugs for Angiogenesis-related Disease from 2019 to 2024.
Chapter 3, the Anti-VEGF Drugs for Angiogenesis-related Disease competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-VEGF Drugs for Angiogenesis-related Disease breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Anti-VEGF Drugs for Angiogenesis-related Disease market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGF Drugs for Angiogenesis-related Disease.
Chapter 14 and 15, to describe Anti-VEGF Drugs for Angiogenesis-related Disease sales channel, distributors, customers, research findings and conclusion.
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
The Global Info Research report includes an overview of the development of the Anti-VEGF Drugs for Angiogenesis-related Disease industry chain, the market status of Tumor (Ranibizumab, Brolucizumab), Eye Diseases (Ranibizumab, Brolucizumab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Anti-VEGF Drugs for Angiogenesis-related Disease.
Regionally, the report analyzes the Anti-VEGF Drugs for Angiogenesis-related Disease markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Anti-VEGF Drugs for Angiogenesis-related Disease market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Anti-VEGF Drugs for Angiogenesis-related Disease market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Anti-VEGF Drugs for Angiogenesis-related Disease industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Ranibizumab, Brolucizumab).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Anti-VEGF Drugs for Angiogenesis-related Disease market.
Regional Analysis: The report involves examining the Anti-VEGF Drugs for Angiogenesis-related Disease market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Anti-VEGF Drugs for Angiogenesis-related Disease market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Anti-VEGF Drugs for Angiogenesis-related Disease:
Company Analysis: Report covers individual Anti-VEGF Drugs for Angiogenesis-related Disease manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Anti-VEGF Drugs for Angiogenesis-related Disease This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Tumor, Eye Diseases).
Technology Analysis: Report covers specific technologies relevant to Anti-VEGF Drugs for Angiogenesis-related Disease. It assesses the current state, advancements, and potential future developments in Anti-VEGF Drugs for Angiogenesis-related Disease areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Anti-VEGF Drugs for Angiogenesis-related Disease market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Anti-VEGF Drugs for Angiogenesis-related Disease market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Ranibizumab
- Brolucizumab
- Aflibercept
- Conbercept
- Faricimab
- Others
- Tumor
- Eye Diseases
- Others
- Roche
- Bayer
- Genentech
- Novartis
- Coherus BioSciences Inc.
- Regeneron
- Qilu Pharmaceutical Co.,Ltd.
- Innovent Biologics
- Anke Biotechnology
- Shenzhen Kangzhe Pharmaceutical Co Ltd
- Chengdu Kanghong Pharmaceutical Group
- Rongchang Biology
- Youzhiyou Bio
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Anti-VEGF Drugs for Angiogenesis-related Disease product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease, with price, sales, revenue and global market share of Anti-VEGF Drugs for Angiogenesis-related Disease from 2019 to 2024.
Chapter 3, the Anti-VEGF Drugs for Angiogenesis-related Disease competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-VEGF Drugs for Angiogenesis-related Disease breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Anti-VEGF Drugs for Angiogenesis-related Disease market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGF Drugs for Angiogenesis-related Disease.
Chapter 14 and 15, to describe Anti-VEGF Drugs for Angiogenesis-related Disease sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Anti-VEGF Drugs for Angiogenesis-related Disease
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Ranibizumab
1.3.3 Brolucizumab
1.3.4 Aflibercept
1.3.5 Conbercept
1.3.6 Faricimab
1.3.7 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Tumor
1.4.3 Eye Diseases
1.4.4 Others
1.5 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size & Forecast
1.5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (2019-2030)
1.5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.1.4 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Roche Recent Developments/Updates
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.2.4 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Bayer Recent Developments/Updates
2.3 Genentech
2.3.1 Genentech Details
2.3.2 Genentech Major Business
2.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.3.4 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Genentech Recent Developments/Updates
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.4.4 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novartis Recent Developments/Updates
2.5 Coherus BioSciences Inc.
2.5.1 Coherus BioSciences Inc. Details
2.5.2 Coherus BioSciences Inc. Major Business
2.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.5.4 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Coherus BioSciences Inc. Recent Developments/Updates
2.6 Regeneron
2.6.1 Regeneron Details
2.6.2 Regeneron Major Business
2.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.6.4 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Regeneron Recent Developments/Updates
2.7 Qilu Pharmaceutical Co.,Ltd.
2.7.1 Qilu Pharmaceutical Co.,Ltd. Details
2.7.2 Qilu Pharmaceutical Co.,Ltd. Major Business
2.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.7.4 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
2.8 Innovent Biologics
2.8.1 Innovent Biologics Details
2.8.2 Innovent Biologics Major Business
2.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.8.4 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Innovent Biologics Recent Developments/Updates
2.9 Anke Biotechnology
2.9.1 Anke Biotechnology Details
2.9.2 Anke Biotechnology Major Business
2.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.9.4 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Anke Biotechnology Recent Developments/Updates
2.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
2.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Details
2.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Major Business
2.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
2.11 Chengdu Kanghong Pharmaceutical Group
2.11.1 Chengdu Kanghong Pharmaceutical Group Details
2.11.2 Chengdu Kanghong Pharmaceutical Group Major Business
2.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.11.4 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
2.12 Rongchang Biology
2.12.1 Rongchang Biology Details
2.12.2 Rongchang Biology Major Business
2.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.12.4 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Rongchang Biology Recent Developments/Updates
2.13 Youzhiyou Bio
2.13.1 Youzhiyou Bio Details
2.13.2 Youzhiyou Bio Major Business
2.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.13.4 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Youzhiyou Bio Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY MANUFACTURER
3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Manufacturer (2019-2024)
3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Manufacturer (2019-2024)
3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Anti-VEGF Drugs for Angiogenesis-related Disease by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer Market Share in 2023
3.4.2 Top 6 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer Market Share in 2023
3.5 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Overall Company Footprint Analysis
3.5.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Region Footprint
3.5.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
3.5.3 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region
4.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2030)
4.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2030)
4.1.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2019-2030)
4.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
4.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
4.4 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
4.5 South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
4.6 Middle East and Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type (2019-2030)
5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
6.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application (2019-2030)
6.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
7.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
7.3 North America Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
7.3.1 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2030)
7.3.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
8.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
8.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
8.3.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2030)
8.3.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region
9.3.1 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
10.2 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
10.3 South America Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
10.3.1 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2030)
10.3.2 South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
11.3.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
12.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market Restraints
12.3 Anti-VEGF Drugs for Angiogenesis-related Disease Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Anti-VEGF Drugs for Angiogenesis-related Disease and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-VEGF Drugs for Angiogenesis-related Disease
13.3 Anti-VEGF Drugs for Angiogenesis-related Disease Production Process
13.4 Anti-VEGF Drugs for Angiogenesis-related Disease Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-VEGF Drugs for Angiogenesis-related Disease Typical Distributors
14.3 Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Anti-VEGF Drugs for Angiogenesis-related Disease
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Ranibizumab
1.3.3 Brolucizumab
1.3.4 Aflibercept
1.3.5 Conbercept
1.3.6 Faricimab
1.3.7 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Tumor
1.4.3 Eye Diseases
1.4.4 Others
1.5 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size & Forecast
1.5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (2019-2030)
1.5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.1.4 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Roche Recent Developments/Updates
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.2.4 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Bayer Recent Developments/Updates
2.3 Genentech
2.3.1 Genentech Details
2.3.2 Genentech Major Business
2.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.3.4 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Genentech Recent Developments/Updates
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.4.4 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novartis Recent Developments/Updates
2.5 Coherus BioSciences Inc.
2.5.1 Coherus BioSciences Inc. Details
2.5.2 Coherus BioSciences Inc. Major Business
2.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.5.4 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Coherus BioSciences Inc. Recent Developments/Updates
2.6 Regeneron
2.6.1 Regeneron Details
2.6.2 Regeneron Major Business
2.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.6.4 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Regeneron Recent Developments/Updates
2.7 Qilu Pharmaceutical Co.,Ltd.
2.7.1 Qilu Pharmaceutical Co.,Ltd. Details
2.7.2 Qilu Pharmaceutical Co.,Ltd. Major Business
2.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.7.4 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
2.8 Innovent Biologics
2.8.1 Innovent Biologics Details
2.8.2 Innovent Biologics Major Business
2.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.8.4 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Innovent Biologics Recent Developments/Updates
2.9 Anke Biotechnology
2.9.1 Anke Biotechnology Details
2.9.2 Anke Biotechnology Major Business
2.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.9.4 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Anke Biotechnology Recent Developments/Updates
2.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
2.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Details
2.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Major Business
2.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
2.11 Chengdu Kanghong Pharmaceutical Group
2.11.1 Chengdu Kanghong Pharmaceutical Group Details
2.11.2 Chengdu Kanghong Pharmaceutical Group Major Business
2.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.11.4 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
2.12 Rongchang Biology
2.12.1 Rongchang Biology Details
2.12.2 Rongchang Biology Major Business
2.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.12.4 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Rongchang Biology Recent Developments/Updates
2.13 Youzhiyou Bio
2.13.1 Youzhiyou Bio Details
2.13.2 Youzhiyou Bio Major Business
2.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
2.13.4 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Youzhiyou Bio Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY MANUFACTURER
3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Manufacturer (2019-2024)
3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Manufacturer (2019-2024)
3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Anti-VEGF Drugs for Angiogenesis-related Disease by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer Market Share in 2023
3.4.2 Top 6 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer Market Share in 2023
3.5 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Overall Company Footprint Analysis
3.5.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Region Footprint
3.5.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
3.5.3 Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region
4.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2030)
4.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2030)
4.1.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2019-2030)
4.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
4.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
4.4 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
4.5 South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
4.6 Middle East and Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
5.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type (2019-2030)
5.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
6.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application (2019-2030)
6.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
7.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
7.3 North America Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
7.3.1 North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2030)
7.3.2 North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
8.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
8.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
8.3.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2030)
8.3.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Region
9.3.1 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
10.2 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
10.3 South America Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
10.3.1 South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2030)
10.3.2 South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country
11.3.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
12.2 Anti-VEGF Drugs for Angiogenesis-related Disease Market Restraints
12.3 Anti-VEGF Drugs for Angiogenesis-related Disease Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Anti-VEGF Drugs for Angiogenesis-related Disease and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-VEGF Drugs for Angiogenesis-related Disease
13.3 Anti-VEGF Drugs for Angiogenesis-related Disease Production Process
13.4 Anti-VEGF Drugs for Angiogenesis-related Disease Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-VEGF Drugs for Angiogenesis-related Disease Typical Distributors
14.3 Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 6. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Roche Recent Developments/Updates
Table 8. Bayer Basic Information, Manufacturing Base and Competitors
Table 9. Bayer Major Business
Table 10. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 11. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Bayer Recent Developments/Updates
Table 13. Genentech Basic Information, Manufacturing Base and Competitors
Table 14. Genentech Major Business
Table 15. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 16. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Genentech Recent Developments/Updates
Table 18. Novartis Basic Information, Manufacturing Base and Competitors
Table 19. Novartis Major Business
Table 20. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 21. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Novartis Recent Developments/Updates
Table 23. Coherus BioSciences Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Coherus BioSciences Inc. Major Business
Table 25. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 26. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Coherus BioSciences Inc. Recent Developments/Updates
Table 28. Regeneron Basic Information, Manufacturing Base and Competitors
Table 29. Regeneron Major Business
Table 30. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 31. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Regeneron Recent Developments/Updates
Table 33. Qilu Pharmaceutical Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 34. Qilu Pharmaceutical Co.,Ltd. Major Business
Table 35. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 36. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
Table 38. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 39. Innovent Biologics Major Business
Table 40. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 41. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Innovent Biologics Recent Developments/Updates
Table 43. Anke Biotechnology Basic Information, Manufacturing Base and Competitors
Table 44. Anke Biotechnology Major Business
Table 45. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 46. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Anke Biotechnology Recent Developments/Updates
Table 48. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Manufacturing Base and Competitors
Table 49. Shenzhen Kangzhe Pharmaceutical Co Ltd Major Business
Table 50. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 51. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
Table 53. Chengdu Kanghong Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 54. Chengdu Kanghong Pharmaceutical Group Major Business
Table 55. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 56. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 58. Rongchang Biology Basic Information, Manufacturing Base and Competitors
Table 59. Rongchang Biology Major Business
Table 60. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 61. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Rongchang Biology Recent Developments/Updates
Table 63. Youzhiyou Bio Basic Information, Manufacturing Base and Competitors
Table 64. Youzhiyou Bio Major Business
Table 65. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 66. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. Youzhiyou Bio Recent Developments/Updates
Table 68. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 69. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Manufacturer (2019-2024) & (USD Million)
Table 70. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 71. Market Position of Manufacturers in Anti-VEGF Drugs for Angiogenesis-related Disease, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 72. Head Office and Anti-VEGF Drugs for Angiogenesis-related Disease Production Site of Key Manufacturer
Table 73. Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
Table 74. Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
Table 75. Anti-VEGF Drugs for Angiogenesis-related Disease New Market Entrants and Barriers to Market Entry
Table 76. Anti-VEGF Drugs for Angiogenesis-related Disease Mergers, Acquisition, Agreements, and Collaborations
Table 77. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2024) & (K Units)
Table 78. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2025-2030) & (K Units)
Table 79. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2024) & (USD Million)
Table 80. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2025-2030) & (USD Million)
Table 81. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2019-2024) & (US$/Unit)
Table 82. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2025-2030) & (US$/Unit)
Table 83. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 84. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 85. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type (2019-2024) & (USD Million)
Table 86. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type (2025-2030) & (USD Million)
Table 87. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2024) & (US$/Unit)
Table 88. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2025-2030) & (US$/Unit)
Table 89. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 90. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 91. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application (2019-2024) & (USD Million)
Table 92. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application (2025-2030) & (USD Million)
Table 93. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2024) & (US$/Unit)
Table 94. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2025-2030) & (US$/Unit)
Table 95. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 96. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 97. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 98. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 99. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2024) & (K Units)
Table 100. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2025-2030) & (K Units)
Table 101. North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2024) & (USD Million)
Table 102. North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2025-2030) & (USD Million)
Table 103. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 104. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 105. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 106. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 107. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2024) & (K Units)
Table 108. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2025-2030) & (K Units)
Table 109. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2024) & (USD Million)
Table 110. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2025-2030) & (USD Million)
Table 111. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 112. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 113. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 114. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 115. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2024) & (K Units)
Table 116. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2025-2030) & (K Units)
Table 117. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2024) & (USD Million)
Table 118. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2025-2030) & (USD Million)
Table 119. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 120. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 121. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 122. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 123. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2024) & (K Units)
Table 124. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2025-2030) & (K Units)
Table 125. South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2024) & (USD Million)
Table 126. South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2025-2030) & (USD Million)
Table 127. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 128. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 129. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 130. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 131. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2024) & (K Units)
Table 132. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2025-2030) & (K Units)
Table 133. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2024) & (USD Million)
Table 134. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2025-2030) & (USD Million)
Table 135. Anti-VEGF Drugs for Angiogenesis-related Disease Raw Material
Table 136. Key Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease Raw Materials
Table 137. Anti-VEGF Drugs for Angiogenesis-related Disease Typical Distributors
Table 138. Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers
LIST OF FIGURE
s
Figure 1. Anti-VEGF Drugs for Angiogenesis-related Disease Picture
Figure 2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Type in 2023
Figure 4. Ranibizumab Examples
Figure 5. Brolucizumab Examples
Figure 6. Aflibercept Examples
Figure 7. Conbercept Examples
Figure 8. Faricimab Examples
Figure 9. Others Examples
Figure 10. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 11. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Application in 2023
Figure 12. Tumor Examples
Figure 13. Eye Diseases Examples
Figure 14. Others Examples
Figure 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (2019-2030) & (K Units)
Figure 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (2019-2030) & (US$/Unit)
Figure 19. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Manufacturer in 2023
Figure 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Manufacturer in 2023
Figure 21. Producer Shipments of Anti-VEGF Drugs for Angiogenesis-related Disease by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 22. Top 3 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer (Consumption Value) Market Share in 2023
Figure 23. Top 6 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer (Consumption Value) Market Share in 2023
Figure 24. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Region (2019-2030)
Figure 25. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Region (2019-2030)
Figure 26. North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 27. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 28. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 29. South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 30. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 31. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 32. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Type (2019-2030)
Figure 33. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2030) & (US$/Unit)
Figure 34. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 35. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Application (2019-2030)
Figure 36. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2030) & (US$/Unit)
Figure 37. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 38. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 39. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Country (2019-2030)
Figure 40. North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Country (2019-2030)
Figure 41. United States Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Canada Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 43. Mexico Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 44. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 45. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 46. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Country (2019-2030)
Figure 47. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Country (2019-2030)
Figure 48. Germany Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. France Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. United Kingdom Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Russia Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. Italy Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 54. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 55. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Region (2019-2030)
Figure 56. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Region (2019-2030)
Figure 57. China Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Korea Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. India Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. Southeast Asia Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. Australia Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 64. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 65. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Country (2019-2030)
Figure 66. South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Country (2019-2030)
Figure 67. Brazil Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 68. Argentina Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 69. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 70. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 71. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Region (2019-2030)
Figure 72. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Region (2019-2030)
Figure 73. Turkey Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Egypt Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Saudi Arabia Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 76. South Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 77. Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
Figure 78. Anti-VEGF Drugs for Angiogenesis-related Disease Market Restraints
Figure 79. Anti-VEGF Drugs for Angiogenesis-related Disease Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease in 2023
Figure 82. Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 83. Anti-VEGF Drugs for Angiogenesis-related Disease Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
Table 1. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Roche Basic Information, Manufacturing Base and Competitors
Table 4. Roche Major Business
Table 5. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 6. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Roche Recent Developments/Updates
Table 8. Bayer Basic Information, Manufacturing Base and Competitors
Table 9. Bayer Major Business
Table 10. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 11. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Bayer Recent Developments/Updates
Table 13. Genentech Basic Information, Manufacturing Base and Competitors
Table 14. Genentech Major Business
Table 15. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 16. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Genentech Recent Developments/Updates
Table 18. Novartis Basic Information, Manufacturing Base and Competitors
Table 19. Novartis Major Business
Table 20. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 21. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Novartis Recent Developments/Updates
Table 23. Coherus BioSciences Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Coherus BioSciences Inc. Major Business
Table 25. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 26. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Coherus BioSciences Inc. Recent Developments/Updates
Table 28. Regeneron Basic Information, Manufacturing Base and Competitors
Table 29. Regeneron Major Business
Table 30. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 31. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Regeneron Recent Developments/Updates
Table 33. Qilu Pharmaceutical Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 34. Qilu Pharmaceutical Co.,Ltd. Major Business
Table 35. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 36. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Qilu Pharmaceutical Co.,Ltd. Recent Developments/Updates
Table 38. Innovent Biologics Basic Information, Manufacturing Base and Competitors
Table 39. Innovent Biologics Major Business
Table 40. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 41. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Innovent Biologics Recent Developments/Updates
Table 43. Anke Biotechnology Basic Information, Manufacturing Base and Competitors
Table 44. Anke Biotechnology Major Business
Table 45. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 46. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Anke Biotechnology Recent Developments/Updates
Table 48. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Manufacturing Base and Competitors
Table 49. Shenzhen Kangzhe Pharmaceutical Co Ltd Major Business
Table 50. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 51. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Shenzhen Kangzhe Pharmaceutical Co Ltd Recent Developments/Updates
Table 53. Chengdu Kanghong Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 54. Chengdu Kanghong Pharmaceutical Group Major Business
Table 55. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 56. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. Chengdu Kanghong Pharmaceutical Group Recent Developments/Updates
Table 58. Rongchang Biology Basic Information, Manufacturing Base and Competitors
Table 59. Rongchang Biology Major Business
Table 60. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 61. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Rongchang Biology Recent Developments/Updates
Table 63. Youzhiyou Bio Basic Information, Manufacturing Base and Competitors
Table 64. Youzhiyou Bio Major Business
Table 65. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product and Services
Table 66. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. Youzhiyou Bio Recent Developments/Updates
Table 68. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 69. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Manufacturer (2019-2024) & (USD Million)
Table 70. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 71. Market Position of Manufacturers in Anti-VEGF Drugs for Angiogenesis-related Disease, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 72. Head Office and Anti-VEGF Drugs for Angiogenesis-related Disease Production Site of Key Manufacturer
Table 73. Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Type Footprint
Table 74. Anti-VEGF Drugs for Angiogenesis-related Disease Market: Company Product Application Footprint
Table 75. Anti-VEGF Drugs for Angiogenesis-related Disease New Market Entrants and Barriers to Market Entry
Table 76. Anti-VEGF Drugs for Angiogenesis-related Disease Mergers, Acquisition, Agreements, and Collaborations
Table 77. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2024) & (K Units)
Table 78. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2025-2030) & (K Units)
Table 79. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2024) & (USD Million)
Table 80. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2025-2030) & (USD Million)
Table 81. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2019-2024) & (US$/Unit)
Table 82. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Region (2025-2030) & (US$/Unit)
Table 83. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 84. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 85. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type (2019-2024) & (USD Million)
Table 86. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type (2025-2030) & (USD Million)
Table 87. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2024) & (US$/Unit)
Table 88. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2025-2030) & (US$/Unit)
Table 89. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 90. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 91. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application (2019-2024) & (USD Million)
Table 92. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application (2025-2030) & (USD Million)
Table 93. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2024) & (US$/Unit)
Table 94. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2025-2030) & (US$/Unit)
Table 95. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 96. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 97. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 98. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 99. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2024) & (K Units)
Table 100. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2025-2030) & (K Units)
Table 101. North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2024) & (USD Million)
Table 102. North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2025-2030) & (USD Million)
Table 103. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 104. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 105. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 106. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 107. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2024) & (K Units)
Table 108. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2025-2030) & (K Units)
Table 109. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2024) & (USD Million)
Table 110. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2025-2030) & (USD Million)
Table 111. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 112. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 113. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 114. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 115. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2024) & (K Units)
Table 116. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2025-2030) & (K Units)
Table 117. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2024) & (USD Million)
Table 118. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2025-2030) & (USD Million)
Table 119. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 120. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 121. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 122. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 123. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2019-2024) & (K Units)
Table 124. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Country (2025-2030) & (K Units)
Table 125. South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2019-2024) & (USD Million)
Table 126. South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Country (2025-2030) & (USD Million)
Table 127. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2019-2024) & (K Units)
Table 128. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Type (2025-2030) & (K Units)
Table 129. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2019-2024) & (K Units)
Table 130. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Application (2025-2030) & (K Units)
Table 131. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2019-2024) & (K Units)
Table 132. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity by Region (2025-2030) & (K Units)
Table 133. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2019-2024) & (USD Million)
Table 134. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Region (2025-2030) & (USD Million)
Table 135. Anti-VEGF Drugs for Angiogenesis-related Disease Raw Material
Table 136. Key Manufacturers of Anti-VEGF Drugs for Angiogenesis-related Disease Raw Materials
Table 137. Anti-VEGF Drugs for Angiogenesis-related Disease Typical Distributors
Table 138. Anti-VEGF Drugs for Angiogenesis-related Disease Typical Customers
LIST OF FIGURE
s
Figure 1. Anti-VEGF Drugs for Angiogenesis-related Disease Picture
Figure 2. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Type in 2023
Figure 4. Ranibizumab Examples
Figure 5. Brolucizumab Examples
Figure 6. Aflibercept Examples
Figure 7. Conbercept Examples
Figure 8. Faricimab Examples
Figure 9. Others Examples
Figure 10. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 11. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Application in 2023
Figure 12. Tumor Examples
Figure 13. Eye Diseases Examples
Figure 14. Others Examples
Figure 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity (2019-2030) & (K Units)
Figure 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price (2019-2030) & (US$/Unit)
Figure 19. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Manufacturer in 2023
Figure 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Manufacturer in 2023
Figure 21. Producer Shipments of Anti-VEGF Drugs for Angiogenesis-related Disease by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 22. Top 3 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer (Consumption Value) Market Share in 2023
Figure 23. Top 6 Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturer (Consumption Value) Market Share in 2023
Figure 24. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Region (2019-2030)
Figure 25. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Region (2019-2030)
Figure 26. North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 27. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 28. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 29. South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 30. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value (2019-2030) & (USD Million)
Figure 31. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 32. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Type (2019-2030)
Figure 33. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Type (2019-2030) & (US$/Unit)
Figure 34. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 35. Global Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Application (2019-2030)
Figure 36. Global Anti-VEGF Drugs for Angiogenesis-related Disease Average Price by Application (2019-2030) & (US$/Unit)
Figure 37. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 38. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 39. North America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Country (2019-2030)
Figure 40. North America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Country (2019-2030)
Figure 41. United States Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Canada Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 43. Mexico Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 44. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 45. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 46. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Country (2019-2030)
Figure 47. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Country (2019-2030)
Figure 48. Germany Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. France Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. United Kingdom Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Russia Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. Italy Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 53. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 54. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 55. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Region (2019-2030)
Figure 56. Asia-Pacific Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Region (2019-2030)
Figure 57. China Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Korea Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. India Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. Southeast Asia Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. Australia Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 63. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 64. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 65. South America Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Country (2019-2030)
Figure 66. South America Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Country (2019-2030)
Figure 67. Brazil Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 68. Argentina Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 69. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Type (2019-2030)
Figure 70. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Application (2019-2030)
Figure 71. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Quantity Market Share by Region (2019-2030)
Figure 72. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value Market Share by Region (2019-2030)
Figure 73. Turkey Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Egypt Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Saudi Arabia Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 76. South Africa Anti-VEGF Drugs for Angiogenesis-related Disease Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 77. Anti-VEGF Drugs for Angiogenesis-related Disease Market Drivers
Figure 78. Anti-VEGF Drugs for Angiogenesis-related Disease Market Restraints
Figure 79. Anti-VEGF Drugs for Angiogenesis-related Disease Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease in 2023
Figure 82. Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 83. Anti-VEGF Drugs for Angiogenesis-related Disease Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source
